D. E. Shaw & Co., Inc. Bio N Tech Se Put Options Transaction History

D. E. Shaw & Co., Inc.

13 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$78.36 - $124.66 $1.33 Million - $2.12 Million	17,000 Added 9.25%	200,800 $23.8 Million
Q2 2024 Aug 14, 2024	SELL	$80.36 - $102.87 $120,540 - $154,305	-1,500 Reduced 0.81%	183,800 $14.8 Million
Q1 2024 May 15, 2024	BUY	$88.96 - $112.35 $62,271 - $78,645	700 Added 0.38%	185,300 $17.1 Million
Q3 2023 Nov 14, 2023	BUY	$98.5 - $125.08 $2.48 Million - $3.15 Million	25,200 Added 15.81%	184,600 $20.1 Million
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $13.3 Million - $16.8 Million	129,400 Added 431.33%	159,400 $17.2 Million
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $9.19 Million - $11.5 Million	-75,000 Reduced 71.43%	30,000 $3.74 Million
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $4.23 Million - $6.06 Million	-33,100 Reduced 23.97%	105,000 $14.2 Million
Q2 2022 Aug 15, 2022	SELL	$123.25 - $186.24 $11.3 Million - $17 Million	-91,400 Reduced 39.83%	138,100 $20.6 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $13.4 Million - $24.5 Million	-105,800 Reduced 31.55%	229,500 $39.1 Million
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $23.8 Million - $39.9 Million	110,000 Added 48.82%	335,300 $86.4 Million
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $15.6 Million - $33.9 Million	75,800 Added 50.7%	225,300 $61.5 Million
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $14.7 Million - $31.3 Million	129,500 Added 647.5%	149,500 $33.5 Million
Q1 2021 May 17, 2021	BUY	$85.73 - $119.5 $1.71 Million - $2.39 Million	20,000 New	20,000 $2.18 Million

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.